Replimune Group, Inc. reports clinical, regulatory and financial developments for a clinical-stage biotechnology business developing oncolytic immunotherapies for cancer. The company’s proprietary RPx platform uses an engineered HSV-1 backbone intended to promote tumor cell killing, immunogenic cell death and systemic anti-tumor immune responses.
Recurring Replimune news centers on RP1, or vusolimogene oderparepvec, including data from the IGNYTE clinical trial, combination use with nivolumab in advanced melanoma, Biologics License Application activity and FDA complete response letters. Updates also cover RP2 clinical data in advanced solid tumors, scientific presentations at oncology meetings, quarterly financial results, research and development spending, cash runway commentary and management presentations at healthcare conferences.
Replimune Group, Inc. (NASDAQ: REPL) reported fiscal Q4 and year-end financial results as of March 31, 2020. The net loss was $15.8 million for Q4 and $52.6 million for the fiscal year, an increase from $6.7 million and $30.8 million in the prior year. Cash and equivalents increased to $168.6 million from $134.8 million. Clinical updates revealed promising data for RP1 in treating cutaneous squamous cell carcinoma and melanoma. The firm is set to expand its clinical development into non-small cell lung cancer (NSCLC) and has completed a new manufacturing facility.
Summary not available.